Lean body mass and amikacin dosage

Hallynck, Th.; Soep, H.; Thomis, J. A.; Boelaert, Johan R.; Daneels, R; Rubinstein, Ethan; Reeves, D. S.; Fillastre, J P

doi:10.1093/jac/6.2.286

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The model has been described in detail by Hallynck et al [5][6][7][8]. LBM of each patient is calculated from weight (W) and height (H) by means of a formu la modified by Hallynck and co-workers from the equation described by James [9].…”

Section: Pharmacokinetic Modelmentioning

confidence: 99%

“…Moreover, the dosage regimens are mostly based on total body weight. As aminoglycosides distri bute in the free body water and the extra cellular volume is correlated with the lean body mass (LBM), dosing according to LBM rather than total body weight seems preferable in patients with normal renal function [5], Hallynck et al [5] also recent ly developed a pharmacokinetic model and a dosage regimen for amikacin in pa- In the present study, the validity and the applicability of this dosage regimen was tested in patients during treatment with amikacin for serious bacterial infec tions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Application of Amikacin Dosage Based upon Lean Body Mass in Patients with Different Renal Function

Wagenvoort¹,

Fieren²,

Goessens³

et al. 1984

Chemotherapy

View full text Add to dashboard Cite

To determine an adequate dosage of amikacin, a pharmacokinetic model was used based on lean body mass (LBM), age and serum creatinine. Amikacin was administered during a mean period of 7 days to patients with normal (group I, n = 15, CCr > 60 ml/min), impaired stable (serum creatinine within a range of 50 μmol/l), (group II, n = 10) and unstable (group III, n = 8) renal function. The mean trough and peak blood levels were < 2 and 24, 4.5 and 25 and 7 and 26 μg/ml in groups I, II and III, respectively. In group II and III a maximum trough level of 10 instead of 5 μg/ml was permitted to prevent a prolonged period of low subtherapeutic levels. With this modification the regimen in both groups appeared satisfactory. The pharmacokinetic model allows an accurate dosage regimen in all groups and can easily be programmed into a pocket calculator.

show abstract

Section: Pharmacokinetic Modelmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical Application of Amikacin Dosage Based upon Lean Body Mass in Patients with Different Renal Function

Wagenvoort¹,

Fieren²,

Goessens³

et al. 1984

Chemotherapy

View full text Add to dashboard Cite

show abstract

Therapeutic drug monitoring of aminoglycoside antibiotics

Reeves

1980

Infection

View full text Add to dashboard Cite

Kinetic parameters of amikacin in cystic fibrosis children

et al. 1987

View full text Add to dashboard Cite

35 kinetic studies have been performed, in nine CF children three to 15 years old; six kinetic studies were performed in four non-CF children, one to 12 years old. The dosage was 5 to 12.5 mg/kg, i.v. during 0.5 to 1.0 h, three to four times per day. Amikacin concentrations were measured in the plasma of all children, and in the sputum of CF-patients, by fluorescent polarization (TDX Abbott). The pharmacokinetic parameters in the plasma did not differ significantly in both groups of patients. In CF children t1/2 = 0.94 h (SD = 0.25 h), Vd (area) = 0.257 l/kg (SD = 0.06 l/kg), total body clearance = 130.7 ml/min/1.73 m2 (SD = 32.4 ml/min/1.73 m2). In non-CF children t1/2 = 0.83 h (SD = 0.15 h), Vd (area) = 0.265 l/kg (SD = 0.04 l/kg) and clearance = 155 ml/min/1.73 m2 (SD = 17.4 ml/min/1.73 m2). The parameters were not affected by the dosage of amikacin. The peak plasma concentrations ranged from 19 to 43.8 mg/l. Amikacin peak level in the sputum of CF children never reached the average MIC (4 mg/l) of Pseudomonas aeruginosa strains isolated in these patients. Amikacin concentration in the sputum reached its highest value about 2 h after the completion of i.v. infusion and was directly related to the peak plasma concentration. According to these parameters, the best dosage regimen appeared to be 7.5 to 8 mg/kg or 225 to 240 mg/m2 administered intravenously in 1.0 h, three times per day.

show abstract

Lean body mass and amikacin dosage

Cited by 5 publications

References 0 publications

Clinical Application of Amikacin Dosage Based upon Lean Body Mass in Patients with Different Renal Function

Clinical Application of Amikacin Dosage Based upon Lean Body Mass in Patients with Different Renal Function

Therapeutic drug monitoring of aminoglycoside antibiotics

Kinetic parameters of amikacin in cystic fibrosis children

Contact Info

Product

Resources

About